Alterity Therapeutics Completes 1-for-50 Reverse Stock Split
ATHE sits 50% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has completed its 1-for-50 reverse stock split, making the previously approved capital consolidation effective immediately.
Key Events · Corporate Governance and Compliance · ATHE
-
Reverse Stock Split Completed
The company has completed the 1-for-50 consolidation of its issued capital, as approved by shareholders on May 29, 2026.
-
New Capital Structure Effective
Post-consolidation, the company now has 217,508,862 ordinary fully paid shares, along with various classes of options, with fractional entitlements rounded up.
-
Trading Commences on New Basis
Normal trading on a T+2 settlement basis under ASX code 'ATH' commenced today, June 12, 2026, reflecting the new share structure.
Analysis · ATHE · Life Sciences
Alterity Therapeutics has finalized its 1-for-50 reverse stock split, an action previously approved by shareholders on May 29, 2026. This consolidation significantly reduces the number of outstanding shares while proportionally increasing the share price, often undertaken to meet exchange listing requirements or enhance investor perception. The new capital structure is now effective, with normal trading commencing today.
At the time of this filing, ATHE was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.2M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.